Combination of gemcitabine and cisplatin in the treatment of patients with non-small-cell lung cancer
- VernacularTitle:吉西他滨联合顺铂治疗非小细胞肺癌
- Author:
Jingxian GUAN
;
Shiying YU
;
Hong QIU
;
Al ET
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
gemcitabine;
cisplatin;
chemotherapy
- From:China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the efficacy, toxicity and side effects of the combination of gemcitabine and cisplatin in the treatment of patients with non small cell lung cancer(NSCLC).Methods:35 patients with NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received gemcitabine 1 000 mg/m 2 on d 1,8 and 15 and cisplatin 80 mg/m 2 on d 1 of 28 day cycle (4 week regiment), or received gemcitabine 1 200 mg/m 2 on d 1,8 and cisplain 80 mg/m 2 on d 8 of the 21 day cycle (3 week regiment). Results:28 of all the cases could be evaluated. The total response rate was 53.6% (all of them were partial response). Response rate of 4 week regiment and 3 week regiment were 58.3% and 50.0%, there was no significant difference between the two groups. The major toxicity and side effects included leucopenia and thromasthenia, but they were acceptable. Conclusions:The combination of gemcitabine and cisplatin is an effective and tolerable regiment in the treatment of NSCLC. Further study on the efficacy, toxicity and side effects in the treatment of NSCLC with different regimens should be carried out in the future.
